Lutris Pharma
Anticancer Therapy for Patients Treated with EGFR Inhibitors
Active
Seed
Startup
Tel Aviv-Yafo
Founded 2015-12
Lutris Pharma is developing the topical B-Raf inhibitor LUT014, a proprietary small molecule allowing administration of epidermal growth factor receptor (EGFR) inhibitors to patients without the interruptions caused by typical cutaneous side effects. Leveraging the paradoxical effect of B-Raf inhibitors, LUT014 decreases dermal toxicities associated with EG…
SectorHealth Tech & Life Sciences
StageSeed
Total raised$40.7M
Employees6
Founded2015-12
HQTel Aviv-Yafo
Crunchbaselutris-pharma
Patents1
Confidence89
Sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technology
BiologicalsMoleculesCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals